Clinical trials: Stage IIIB Non-Small Cell Lung Cancer
Lung Cancer
Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003589
- Testing
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 33 sites in Belgium, Czechia and 10 more
- Volunteers
- 450 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
ALK Positive, NSCLC Stage IIIB
Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
The experimental design is exploratory, single-arm, multi-center, real-world research. Ensatinib 225mg qd A prospective and exploratory real-world study of Ensatinib for ALK-positive advanced non-small cell lung cancer patients…
- Conditions
- ALK Positive, NSCLC Stage IIIB, NSCLC Stage IV
- Trial name
- EFLRWR (NCT05132218)
- Testing
- Ensatinib
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non Small Cell Lung Cancer
Trial of Poor Performance Status Patients (ToPPS)
The purpose of this trial is to evaluate three treatment regimens in patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) with a performance status of 2 and who were not previously treated.
- Trial name
- ToPPS (NCT00892710)
- Testing
- Pemetrexed, Bevacizumab, Carboplatin
- Where
- 27 sites in United States
- Volunteers
- 172 people
- Sponsor
- SCRI Development Innovations, LLC
Lung Cancer
Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070486
- Testing
- carboplatin, celecoxib, gemcitabine hydrochloride
- Where
- 75 sites in United States
- Volunteers
- 140 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non Small Cell Lung Cancer
Computer-Generated Quality of Life Assessment Program for Advanced Non-Small Cell Lung Cancer Patients (LUNL2)
In the treatment of advanced cancer, maximizing quality of life (QoL) is a fundamental goal for oncologists and their patients. In order to achieve this goal, some form of systematic and reliable QoL assessment is needed in…
- Trial name
- LUNL2 (NCT01337102)
- Testing
- Physician Receives QoL results, Physician Does not receive the results
- Where
- Canada
- Volunteers
- 103 people
- Sponsor
- University Health Network, Toronto
Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer
Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer
This trial studies efficacy and safety of combination of vitamin C infusion with modulated electro-hyperthermia (mEHT) in treatment of non small cell lung cancer patients.Phase I of this clinical study is to find the tolerable…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- VCONSCLC (NCT02655913)
- Testing
- vitamin C, Modulated Electro-Hyperthermia (mEHT), Supportive care
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Clifford Hospital, Guangzhou, China
NSCLC, Tislelizumab
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of Tislelizumab combined with platinum-based doublet chemotherapy followed by…
- Conditions
- NSCLC, Tislelizumab, Chemotherapy, Hypofractionated Radiotherapy
- Trial name
- NCT07085182
- Testing
- SBRT combined with Tislelizumab followed by Tislelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zibo Municipal Hospital
Non Small Cell Lung Cancer
Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer
In this trial, subjects with chemo-naive advanced non-small cell lung cancer (NSCLC) were assigned to chemotherapy using a genomic-based predictor for platinum sensitivity.
- Trial name
- TOP0602 (NCT00509366)
- Testing
- Cisplatin & Gemcitabine, Cisplatin & Pemetrexed, Docetaxel & Gemcitabine
- Where
- 8 sites in United States
- Volunteers
- 101 people
- Sponsor
- Duke University
Non-small Cell Lung Cancer
A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]
Part A of this study will investigate the Maximum Tolerated Dose of Debio 0932 in combination with standard of care chemotherapy for the first- and second-line treatment of advanced NSCLC.
- Trial name
- HALO (NCT01714037)
- Testing
- Debio 0932, Cisplatin, Pemetrexed
- Where
- 8 sites in France, Spain and 1 more
- Volunteers
- 82 people
- Sponsor
- Debiopharm International SA
Lung Cancer
Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have stage IIIB…
- Trial name
- NCT00005037
- Testing
- temozolomide
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Fox Chase Cancer Center
Non Small Cell Lung Cancer
Alternating Cycles of Carboplatin/Gemcitabine and Carboplatin/Taxol for Advanced Stage NSCLC
To see the efficacy of using chemotherapies alternatively (carboplatin and gemcitabine alternating with carboplatin and taxol) for pts with stage IIIB (nonresectable and stage IV NSCLC.
- Trial name
- NCT00259675
- Testing
- carboplatin/gemcitabine, carboplatin/taxol
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of Saskatchewan
NSCLC, EGFR Gene Amplification
Combination of Metformin With Gefitinib to Treat NSCLC
The purpose of this study is to determine whether metformin in combination with gefitinib are effective in patients with previously untreated advanced or metastatic Non-Small-Cell Lung cancer with epidermal growth factor receptor…
- Conditions
- NSCLC, EGFR Gene Amplification, Advanced Cancer, Stage IIIB NSCLC
- Trial name
- CGMT (NCT01864681)
- Testing
- Gefitinib and Metformin
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non-small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery [neoadjuvant phase], followed by pembrolizumab alone after surgery…
- Trial name
- NCT03425643
- Testing
- Pembrolizumab, Cisplatin, Gemcitabine
- Where
- 227 sites in United States, Argentina and 23 more
- Volunteers
- 797 people
- Sponsor
- Merck Sharp & Dohme LLC
NSCLC (Advanced Non-small Cell Lung Cancer)
EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients
The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer…
- Trial name
- EMPATHY NSCLC (NCT07096258)
- Where
- 4 sites in France, Italy and 2 more
- Volunteers
- 1,000 people
- Sponsor
- Hedera Dx SA
Lung Cancer
Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00795340
- Testing
- carboplatin, cediranib maleate, paclitaxel
- Where
- 19 sites in Brazil, Canada
- Volunteers
- 306 people
- Sponsor
- NCIC Clinical Trials Group
Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Stage IV
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
- Conditions
- Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Stage IV, Non-Small-Cell Lung Cancer Metastatic, Carcinoma, Non-Small-Cell Lung
- Trial name
- SUNRISE (NCT01999673)
- Testing
- bavituximab, Docetaxel
- Where
- 161 sites in United States, Australia and 12 more
- Volunteers
- 582 people
- Sponsor
- Peregrine Pharmaceuticals
Non-small Cell Lung Cancer
ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy
The goal of this observational study is to explore whether ctDNA-MRD dynamic monitoring can more effectively predict the therapeutic effect of induction chemoimmunotherapy followed by surgery or non-surgical treatment for stage…
- Trial name
- NCT05822284
- Testing
- NGS and ctDNA-MRD detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Xiangya Hospital of Central South University
Febrile Neutropenia, Stage 0 Breast Cancer
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia.
- Conditions
- Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer
- Trial name
- TrACER (NCT02728596)
- Testing
- Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 160 sites in United States, Puerto Rico
- Volunteers
- 3,665 people
- Sponsor
- SWOG Cancer Research Network
Resectable Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8
Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer
This phase II trial studies how well bintrafusp alfa before surgery works in treating patients with non-small cell lung cancer for which the patient has not received treatment in the past (untreated) and that can be removed by…
- Conditions
- Resectable Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8
- Trial name
- NCT04560686
- Testing
- Bintrafusp Alfa, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Non Small Cell Lung Cancer
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
It has been shown in previous studies that the ability to treat lung cancer could be significantly improved by not only targeting the tumor cells directly with chemotherapy, but also by cutting off the blood supply to the cancer…
- Trial name
- NCT00687297
- Testing
- vandetanib induction, Docetaxel, Carboplatin
- Where
- 30 sites in United States
- Volunteers
- 162 people
- Sponsor
- PrECOG, LLC.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.